Current Context : Recently, ZyVac TCV, a typhoid vaccine developed by Zydus Lifesciences Ltd., has received prequalification from the World Health Organization (WHO), making it eligible for United Nations procurement programs.

About ZyVac TCV

• Purpose: ZyVac TCV is a Typhoid Vi conjugate vaccine designed to provide immunity against Salmonella typhi, the bacterium responsible for typhoid fever.
• How It Works: As a conjugate vaccine, it links bacterial antigens to polysaccharides (from the bacterial coat) to effectively trigger the body’s immune response.
• Type: ZyVac TCV is a subunit vaccine, meaning it contains only specific bacterial components to stimulate immunity, minimizing side effects compared to whole-cell vaccines.
• Made in India: The vaccine is fully developed and manufactured in India by Zydus Lifesciences Ltd., showcasing indigenous pharmaceutical capabilities.